Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi（新）
GUSD（纯图）
Rewards

Samsung BioLogics Acquires PolyPeptide Group for 2.7 Trillion Won on July 20

GateNews
Stocks
NICE1.60%
On July 20, Samsung BioLogics announced the acquisition of PolyPeptide Group AG for 2.7 trillion Korean won, according to NICE Credit Rating and Samsung BioLogics' official disclosure. The Swiss peptide contract development and manufacturing organization (CDMO), listed on SIX Swiss Exchange, will be acquired with 100% equity transfer. PolyPeptide Group, founded in 1952 and spun off from pharmaceutical firm Ferring in 1996, operates production facilities across five countries with over 1,000 development and production projects in peptide therapeutics. The company reported 669.2 billion Korean won in revenue and 14.8 billion Korean won in operating profit in 2025. NICE Credit Rating assessed that while the near-term impact on Samsung BioLogics' credit rating remains limited, the company's leverage will increase in the medium term given its existing capex commitments for new campus construction.
View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

10h ago
Samsung BioLogics Acquires Swiss Peptide CDMO PolyPeptide, Target Price Set at 2M KRW
10h ago
Samsung Electro-Mechanics Q2 Operating Profit Forecast at ₩410.4B, Up 92.7% on AI Server Demand
11h ago
Samsung Electronics, SK Hynix Rise in Premarket as US Chip Stocks Draw Bargain Buying
11h ago
Samsung E&A Posts 19% Operating Profit Jump in Q2 on Semiconductor Factory Orders
20h ago
Samsung Biologics Offers $1.8B Cash Bid for Swiss PolyPeptide Group
In-Depth Analysis

Samsung Electro-Mechanics Q2 Operating Profit Forecast Jumps 93% on AI Server Demand

Oliver Grant10h ago

Samsung Biologics to acquire PolyPeptide for KRW 2.7 trillion, creating South Korea’s largest pharma M&A deal

Market Whisper07-20 02:11

Samsung Biologics Acquires PolyPeptide Group for 2.7 Trillion Won in Largest Korean Pharma M&A

Lucas Bennett07-20 00:51
Comment
0/400
No comments